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To date, germline mutations have been found in three candidate genes for hereditary prostate cancer: ELAC2 at 17p11, RNASEL at
1q25 and MSR1 at 8p22. RNASEL, encoding the 20,50-oligoadenylate-dependant RNase L, seems to have rare mutations in different
ethnicities, such as M1I in Afro-Americans, E265X in men of European descent and 471delAAAG in Ashkenazi Jews. In order to
evaluate the relevance of RNASEL in the German population, we sequenced its open reading frame to determine the spectrum and
frequency of germline mutations. The screen included 303 affected men from 136 Caucasian families, of which 45 met the criteria for
hereditary prostate cancer. Variants were analysed using a family-based association test, and genotyped in an additional 227 sporadic
prostate cancer patients and 207 controls. We identified only two sib pairs (1.4% of our families) cosegregating conspicuous RNASEL
variants with prostate cancer: the nonsense mutation E265X, and a new amino-acid substitution (R400P) of unknown functional
relevance. Both alleles were also found at low frequencies (1.4 and 0.5%, respectively) in controls. No significant association of
polymorphisms (I97L, R462Q and D541E) was observed, neither in case–control analyses nor by family-based association tests. In
contrast to previous reports, our study does not suggest that common variants (i.e. R462Q) modify disease risk. Our results are not
consistent with a high penetrance of deleterious RNASEL mutations. Due to the low frequency of germline mutations present in our
sample, RNASEL does not have a significant impact on prostate cancer susceptibility in the German population.
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Familial clustering of prostate cancer, observed in up to 27% of all
cases, has pointed at the existence of major susceptibility genes
that confer a high disease risk. To date, three strong candidates are
known, RNASEL at 1q25 (Carpten et al, 2002), ELAC2 at 17p11
(Tavtigian et al, 2001) and MSR1 at 8p22 (Xu et al, 2002), each
having been identified with germline mutations in prostate cancer
families. Mapping of these genes was preceded by a history of
whole genome and candidate region linkage analyses worldwide
(for a review, see Schaid, 2004). Since evidence of linkage at
particular susceptibility loci seemed to differ substantially between
individual populations, a variable prevalence of particular
susceptibility genes must be taken into consideration. The aim of
the present study is to evaluate the impact of RNASEL on prostate
cancer risk in the central European population of Germany.
The RNASEL gene encodes the 50–20-oligoadenylate-dependant
RNase L, a mediator of the interferon-induced RNA degradation
pathway. Its tumour suppressor potential has been postulated
since the introduction of truncated RNase L protein in murine cells
abolished the antiproliferative effect of interferon (Hassel et al,
1993). The RNASEL gene locus at 1q25 (HPC1) has been implicated
in prostate cancer susceptibility as a result of the first genome wide
linkage scan, which included 91 hereditary prostate cancer
pedigrees from North America and Sweden (Smith et al, 1996).
Linkage to HPC1 seemed to be stronger in families with early-onset
disease. Subsequently, in the initial family collection, the nonsense
mutation E265X was discovered in a Caucasian pedigree. A second
deleterious variation, M1I, was found in a family of African
descent (Carpten et al, 2002). Follow-up studies revealed a
frameshift mutation, 471delAAAG, as a founder allele in Ashkenazi
Jews (Rennert et al, 2002).
In order to determine the frequency and spectrum of RNASEL
germline mutations in our population, we sequenced 303 cases
representing 136 prostate cancer families from Germany, Central
Europe. Conspicuous variants were examined by a family-based
association test and were genotyped in an additional 227 sporadic
cases and 207 controls. Genotypes were further analysed for a
potential correlation with early disease onset.
PATIENTS, MATERIALS AND METHODS
Patients
All individuals described in this report are participants in the
Prostate Cancer Genetics Project of the University of Ulm.
Urologists from all over Germany were asked to inform all
patients with prostate cancer about our project and to motivate
them to contact our institution. Although we did not apply any
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sselection criteria to the primary sampling of these prostate cancer
patients, most of them were contributed by Urological Surgical
Departments from Southern Germany and the majority were
treated by radical prostatectomy. The index’s probands’ self-
reported family history of prostate cancer was used to identify
prostate cancer families. In addition, a detailed family question-
naire was used as a guide for the recruitment of affected and
relevant unaffected relatives. In all cases, the diagnosis of prostate
cancer was confirmed by a histopathological report or by another
suitable medical record. All probands were of Caucasian descent.
In approximately one-third of patients, prostate cancer was
diagnosed from their symptoms. In two-thirds of patients, the
disease was detected by PSA screening. Informed consent,
according to the Institutional Review Board at the University of
Ulm, was mandatory.
The families used in this study were required to have at least two
relatives with confirmed prostate cancer from which blood
samples could be made available. The screening included 136
families with confirmed Mendelian inheritance patterns, of which
45 (33%) matched the criteria for hereditary prostate cancer
according to Carter et al (1993). In all, 58 families (43%) had two
affected relatives, 42 (31%) had three, 29 (21%) had four, and
seven (5%) had five or more affected relatives. Overall, 303 familial
prostate cancer cases were available for genotyping (2.2 per
family). In these probands, the mean age at diagnosis was 63.8
years (47–83 years).
Sporadic cases, where a negative family history of prostate
cancer was reported, were recruited at the University of Ulm
(n¼227). The mean age of diagnosis was 64.1 years (range: 42–
84). For controls we used 207 healthy, elderly men who were not
diagnosed with prostate cancer before. In all, 171 (83%) of the
controls were confirmed to have a negative DRE finding. PSA
levels were available for 72 (35%) controls and were inconspicuous
in these subjects. The mean age at the time of sampling was 57.1
years (range 32–88).
Genetic analysis
DNA was extracted from peripheral blood lymphocytes by
standard procedures. The genomic DNA served as template for
PCR amplification of the coding region of RNASEL with the use of
three primer pairs for the large exon 2, and one pair for each of the
exons 3–7. Oligonucleotides and PCR conditions are given in
Table 1. PCR samples were cleaned up by filtration membrane
plates (Millipore, Schwalbach, Germany) prior to sequencing.
PCRs destinated for SNP genotyping received enzymatic treatment
using 2.5U shrimp alkaline phosphatase and 1.0U exonuclease 1
(USB, Cleveland, USA) per 10ng PCR product. In the case of
multiplex genotyping, PCR products were pooled prior to the
cleaning-up step.
In order to sequence the entire open reading frame from both
directions, sequencing reactions were set up for each PCR
amplification primer and each of the four additional primers
within exon 2 (Table 1). We used BigDye version 3.1 (Applied
Biosystems, Foster City, USA) as recommended by the manufac-
turer in a total volume of 5ml. Samples were lastly filtrated and
analysed on an ABI3100 instrument. Individual sequences were
aligned to a genomic reference sequence (GenBank accession no.
AL138776).
SNP genotyping was performed by a ddNTP primer extension
method. Five nucleotide variations (nt289, nt793, nt1199, nt1385,
nt1623) were genotyped simultaneously in a multiplex assay using
oligonucleotides distinguishable by length. Variation site nt407,
identified later, was assayed separately. Sequences and individual
concentrations of all primers are given in Table 1. On the PCR
templates described above, these primers were elongated at the
variation sites by fluorescently labelled ddNTPs in total reaction
volumes of 5ml, using the multiplex SNaPshot kit (Applied
Biosystems, Foster City, USA). Residual ddNTPs were digested
by calf intestine phosphatase (USB, Cleveland, USA) incubation,
using 0.5U of enzyme. Fragments were separated and detected
with an ABI3100 sequencing system.
Statistical analysis
Family-based association tests were performed with the aid of
the FBAT (Horvath et al, 2001) programme, which is suitable to
estimate transmission patterns within various types of pedigree
structures. FBAT analysis is used here for each individual
marker to test the null hypothesis of no association in the
presence of linkage. The test statistic is based on a linear
combination of offspring genotypes and traits, called S. Here,
Table 1 Oligonucleotides used for PCR amplification, sequencing and genotyping by ddNTP primer extension
PCR and sequencing primers Annealing temperature (1C) Conc. MgCl2 (mM)
ex2-f1: actgctgctctgttgcca ex2-r2: agagcatggatcaaggcat 58 1.5
ex2-1r: cattgacatctgctcctttag Sequencing only
Ex2-2h: gtgctgaccctgttctga Sequencing only
Ex2-f3: acacgtagaggtcttgaag ex2-r3: cacaatctgtactggctcc 51 1.5
Ex2-f4: ctggagcaagagcacata ex2-r5: aatcatccacatttactctag 58 1.5
ex2-4r: ctcccatagaatgtcacca Sequencing only
Ex2-5h: ctacctggggttctatgag Sequencing only
Ex3-f: gcagatacctaacagatcaaa ex3-r: cctactagttctgtccctc 51 1.5
Ex4-h: ctaatagcgtgcaccactc ex4-r: tgatttgcagcccagactt 60 2.0
Ex5-h: acaccaaaatctaacggtt ex5-r: cacctctttgagcctct 53 1.5
Ex6-h: gacacaattatagttagcatt ex6-r: gtaaggcaacagtgatag 53 1.5
Ex7-h: gccatatgctgtgaag ex7-r: ccaaggactctacagctaa 58 1.5
ddNTP-extension primers Final primer Conc. (mM)
rl-407: tttttttttt tttttatgga agccgctgtg tatg 0.02
rl-289: ttttttttttgaatggggccacgcctttt 0.12
rl-793: ctggagcaagagcacata 0.03
rl-1199: ttttttttttttttttttttttgagggcagcccac 0.12
rl-1385: tttttttttttttttttttttgaggaagatgaatttgccc 0.08
rl-1623: tttttttttttttttttttttttttcattactttgagctttcag 0.30
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sphenotypes were specified exclusively for affected persons (trait
score 1), while unaffected and unknown persons were included
only to contribute genotype information (trait score 0). Genetic
variants were analysed under the genetic model of ‘additive’
effects. Under these conditions, S reflects the difference between
the observed number of transmitted A1 alleles at a biallelic locus
(with alleles A1 and A2) to the affected offspring, and the number
E(S) expected under the null hypothesis. S is standardised by
dividing it by its standard deviation, the square root of its variance
Var(S), to form a Z-value. Since genotypes within pedigrees may be
correlated solely due to the presence of linkage (cosegregation), we
used the empirical variance option in order to adjust for this
correlation. The Z-value was finally transferred into a P-value.
For case–control analyses, associations between genotypes
and disease status were assessed by unconditional logistic
regression using the software package StatView (SAS, Cary,
USA). In this context, odds ratios, their 95% confindence
intervals and the corresponding P-values are given. Age of disease
onset data from individuals of different genotypes were compared
by two-sided t-tests.
RESULTS
Variants discovered by the sequencing of RNASEL in
familial prostate cancer probands
All sequence variations identified within the open reading frame of
RNASEL are summarised in Table 2. Among 303 probands from
136 prostate cancer families, we discovered one protein-truncating
variant, nt g793t, that resulted in the previously reported
premature stop codon E265X. This point mutation was present
in two affected brothers of a single family (Figure 1, family
ULM0068). A third brother (individual ULM0068_05), who was
available for genotyping, was analysed subsequently. It was
discovered that he too carried variant E265X, but was to date (69
years of age) not diagnosed with prostate cancer. In all three
siblings, the nonsense mutation was coincident with a further
amino-acid change (G49S). According to earlier reports (Carpten
et al, 2002; Rokman et al, 2002), this seems to be part of a unique
founder haplotype. A second conspicuous finding was a previously
unreported missense variation (R400P). The arginine-to-proline
substitution affected the protein kinase-like domain of RNase L;
however, its functional relevance remains to be determined. The
causal nucleotide exchange, g1199c, cosegregated with the disease
in an affected sib pair with no additional relatives available for
genotyping (Figure 1, family ULM0042). One further rare amino-
acid exchange (G136D) was identified in a single proband, but was
not present in his affected brother (Figure 1, family ULM0170).
Aside from these rare variants, we also observed the common
amino-acid substitutions I97V, R462Q and D541E. Silent exonic
variations included g1179a, c1584a and g2172a.
Family-based association test
A family-based association test was applied in order to examine
the transmission of peptide variants to affected individuals. In
order to increase the information on parental genotypes, an
additional 110 nonaffected male and female family members were
tested at the variation sites G136D, E265X, R400P, I97V, R462Q
and D541E. The rare variants G136D, E265X and R400P were not
recovered in families other than those described above (Figure 1).
All the three were not informative for the analysis. The results of
Table 2 Sequence variants found in 303 familial prostate cancer patients
Observed alleles
Location Nucleotide exchange Amino-acid exchange No. Frequency Also found in previous study population
Exon 2 g175a G59S 2/594 0.003 USA
a,b, Finland
c
Exon 2 a289c I97L 9/600 0.015 USA
a,b,d
Exon 2 g407a G136D 1/600 0.002 Novel
Exon 2 g793t E265X 2/606 0.003 USA
a,b, Finland
c
Exon 2 g1179a — 5/604 0.008 Finland
c
Exon 2 g1199c R400P 2/604 0.003 Novel
Exon 2 g1385a R462Q 245/604 0.406 USA
a,b,d, Finland
c, Japan
e
Exon 4 c1584a — 1/606 0.002 Novel
Exon 4 t1623g D541E 359/606 0.592 USA
a,b,d, Finland
c, Japan
e
Exon 7 g2172a — 24/596 0.040 USA
a,b, Finland
c
aCarpten et al (2002);
bChen et al (2003);
cRokman et al (2002);
dWang et al (2002);
eNakazato et al (2003).
E265X
dx 71 y
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 44 y
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ULM0068 ULM0042 ULM0170 R400P G136D
Figure 1 Pedigrees with conspicuous RNASEL alleles. Carriers of variants are indicated by one filled circle. Two open circles represent wild-type
genotypes.
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sthe remaining polymorphisms are shown in Table 3. A tendency of
overtransmission was observed for the infrequent valine variant at
position 97 (P¼0.17), although only two families contributed to
the test. In contrast, sufficient numbers of informative families (39
and 34, respectively) were available for the common variants
R462Q and D541E. The observed transmissions towards affected
offspring were approximately equal to the expected values, that is,
76 vs 76.2 (P¼0.96), in case of the Q allele at 462, and 81 vs 77.4
(P¼0.37) for the E allele at 541.
Case–control study of RNASEL peptide variants
The genotype frequencies of G136D, E265X, R400P, I97V, R462Q and
D541E were determined in 227 prostate cancer patients with no
familial disease history (sporadic cases) and in 207 healthy men
(controls). Prior to case–control analyses, the observed genotype
counts at all loci were verified to resemble the Hardy–Weinberg
equilibrium: in the control group (P40 . 5 1 ) ,t h es p o r a d i cg r o u p
(P40.45) and in the group of index probands from prostate cancer
families (P40.64). The exchange G136D was seen neither in sporadic
cases, nor in controls. The observations at all other variation sites are
given in Table 4. Overall, we found that none of the genotypes were
significantly associated with either familial, sporadic or the
combined group of prostate cancer. Variants that tended to be
over-represented in cases include the newly identified missense
exchange R400P, which was recovered in two (0.9%) sporadic
prostate cancer cases and in one (0.5%) nonaffected man (OR¼1.83;
CI95¼0.17–20.3; P¼0.62). Also, heterozygous carriers of the valine
allele at codon 97 seemed to be increased in sporadic cases (1.8 vs
1.0%; OR¼1.84; CI95¼0.33–10.1, P¼0.49) and were most frequent
in familial probands (3.0%; OR¼3.13; CI95¼0.57–17.3; P¼0.19).
Rather similar genotype frequencies in the study samples were found
for the common polymorphisms R462Q and D541E. An inverse
distribution was observed for the nonsense mutation E265X, which
was found twice in prostate cancer cases (0.6%, one familial and one
sporadic proband) and three times (1.5%) in controls (OR¼0.38;
CI95¼0.06–2.27; P¼0.29).
Effect of RNASEL variants on early-onset prostate cancer
All 530 prostate cancer patients genotyped for this study were
analysed for a correlation of genotype and age of disease onset. In
a subgroup of 49 cases who were diagnosed at the age of 55 years
or younger, which is commonly assigned as early-onset prostate
cancer, none of the genotypes were significantly over-represented
(Table 5). However, regarding the mean age of onset, the four
carriers of the R400P exchange appeared to be 2 years younger
than wild type (t-test; P¼0.24).
DISCUSSION
The RNASEL gene at 1q25/HPC1 is one of three strong candidate
genes for hereditary prostate cancer known to date. Since
deleterious germline mutations were identified in RNASEL,
growing evidence has been reported for the causal quality of the
potential tumour suppressor gene. Firstly, prostate carcinomas of
mutation carriers were shown to exhibit loss of heterozygosity
(LOH), and, as a consequence, were deficient in functional RNase L
(Carpten et al, 2002). Secondly, a common amino-acid variant,
R462Q, which was previously found to be associated with prostate
cancer risk (Casey et al, 2002), was proven to reduce the affinity of
RNase L to form catalytically active dimers (Xiang et al, 2003).
However, the evaluation of the gene’s impact on prostate cancer
susceptibility requires a sufficient series of epidemiologic data.
Crucial issues include the estimation of the disease risk for
mutation carriers and the description of allele frequencies, which
may differ between populations due to the given locus hetero-
geneity of prostate cancer.
In the present screening of 136 German prostate cancer families,
we discovered two novel missense mutations, aside from the
nonsense mutation E265X. While one of these amino-acid
exchanges (G136D) seemed to be a private mutation in one single
proband, the variant R400P appeared to be present in the
population with a low allele frequency. There are some indications
towards an effect of R400P, like cosegregation with the disease in
the affected sibpair, a higher frequency of carriers among prostate
cancer cases, and a younger age of these patients. An association
with the disease, however, remains unknown, due to the lack of
statistical significance.
On the other hand, no remarkable proportion of our families
could be explained by RNASEL mutations like E265X, although
presently we cannot fully rule out gene deletions or epigenetic
changes which are undetectable by the procedure of exon
sequencing. Consistent with a low number of deleterious RNASEL
variants in our study sample was our recent genomewide linkage
scan, resulting in an insignificant ZLR score of 1.28 (P¼0.10) at
marker D1S218 at 1q25/HPC1 (Maier et al, 2004). However, in
contrast to the entire family collection, some individual pedigrees
have supported linkage to HPC1. The family with the highest
Table 3 Family-based association tests
Variant No. of informative nuclear families Observed transmissions S Expected transmissions E(S) Variance Var(S) ZP
I97L 2 3 1.9 0.6 1.37 0.17
R462Q 39 76 76.2 16.8  0.05 0.96
D541E 34 81 77.4 16.2 0.89 0.37
Table 4 Frequencies of RNASEL protein variants in familial prostate cancer, sporadic prostate cancer and in controls
Genotype
Controls
total 207 n (%)
Sporadic
cases total 227 n (%)
Familial index
cases total 136
a n (%)
Sporadic cases
vscontrols OR (95% CI)
Familial cases vs
controls OR (95% CI)
All cases vs controls
OR (95% CI)
97 IL
b 2 (1.0) 4 (1.8) 4 (3.0) 1.84 (0.33–10.1) 3.13 (0.57–17.3) 2.32 (0.49–11.0)
265 EX
b 3 (1.5) 1 (0.4) 1 (0.7) 0.30 (0.03–2.92) 0.50 (0.05–4.89) 0.38 (0.06–2.27)
400 RP
b 1 (0.5) 2 (0.9) 1 (0.7) 1.83 (0.17–20.3) 1.53 (0.10–24.6) 1.72 (0.18–16.6)
462 RQ 97 (46.9) 102 (44.9) 69 (50.7) 0.86 (0.60–1.31) 1.18 (0.73–1.92) 0.97 (0.66–1.41)
QQ 37 (17.8) 36 (15.9) 23 (16.9) 0.81 (0.46–1.39) 1.03 (0.54–1.96) 0.88 (0.53–1.44)
541 DE 97 (46.9) 112 (49.3) 64 (47.1) 1.13 (0.68–1.88) 1.35 (0.73–2.52) 1.20 (0.75–1.91)
EE 69 (33.3) 73 (32.2) 52 (38.2) 1.03 (0.60–1.78) 1.55 (0.81–2.94) 1.20 (0.73–1.96)
aThe proband with whom initial family contact was made (index case) was chosen to represent the family.
bNo homozygous genotypes were observed for these rare variants.
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sindividual evidence (ZLR¼2.86, P¼0.002), including four affected
first-degree relatives, was checked for RNASEL expression in order
to find further clues for hidden deleterious mutations. In every
proband, transcripts of both alleles were confirmed to be present at
equal amounts, and to be spliced correctly (data not shown).
Taken together, these results indicate that RNASEL could only
account for a minor portion of familial prostate cancer in
Germany. Similar conclusions have been drawn from other
Caucasian populations, where, overall, E265X has so far been
observed as the only truncating RNASEL mutation. It appeared
together with the rare missense variant G49S in study samples
from North America, Scandinavia, and also in Germany, indicating
a founder haplotype of European descent (Carpten et al, 2002;
Rokman et al, 2002, Chen et al, 2003). However, an appreciable
carrier frequency of 4.3% was identified only in families from
Finland, with some lack of cosegregation with the disease (Rokman
et al, 2002). Similar to our study sample, a combined family
collection from the United States and Sweden revealed rare carriers
of E265X (Chen et al, 2003), while no mutations at all were found
in a further American study (Wang et al, 2002).
It is noteworthy that we observed a higher frequency of E265X
mutation carriers in healthy men than in prostate cancer patients.
This rather unexpected finding could be consigned to chance,
owing to our limited sample size. Additional genotyping of 190
unselected blood donors revealed no further heterozygotes of
E265X, suggesting that the frequency in our population could
indeed be somewhat lower. A crucial issue is the validity of the
disease-free status of the three controls carrying the truncating
variant. All the three had a negative DRE, and PSA values were
recorded for two of the men, which were 0.1ngml
 1 by the age of
64 and 0.5ngml
 1 by the age of 55. The prevalence of prostate
cancer is as low as 6.6% among men with these PSA levels (Carter,
2004). Additionally, in our single E265X-positive prostate cancer
family, we identified a male carrier with no evidence of the disease
(DRE normal; PSA¼1.7ngml
 1) at 69 years of age. These data do
not support a high penetrance of deleterious RNASEL mutations.
Regarding the common variants of RNASEL, we did not observe
any significant association, neither with prostate cancer in general
nor with early-onset disease. We cannot exclude that our sample
size may be too small to sufficiently assess a moderate disease
effect of low frequent variants, such as the amino-acid exchange
I97L, which tends to be over-represented in sporadic and familial
prostate cancer. On the other hand, our results regarding frequent
polymorphisms are valid. Especially, the polymorphism R462Q
showed absolutely no correlation with prostate cancer risk in our
case–control study. This finding was further confirmed by our
negative result of a family-based association test. In contrast to
these data, the glutamine residue at 462 was recently suggested to
be responsible for up to 13% of prostate cancer cases (Casey et al,
2002), and was proven to alter the enzyme’s activity (Xiang et al,
2003). Despite this impressive result, two further studies found
disease risk associated with the more frequent arginine allele
(Wang et al, 2002; Nakazato et al, 2003). These inconsistencies
might suggest a cis-acting locus in linkage disequilibrium to the
R462Q polymorphism, where causal variants may reside on diverse
haplotypes and disproportionally show up in different study
populations. A similar hypothesis was discussed earlier as a result
of Wang et al (2002) finding association of the arginine allele
exclusively in familial prostate cancer and not in sporadic disease.
Such findings argue against the plausibilty of a particular variant
always effecting the same functional consequence, unless the true
disease effect is driven by an unknown factor in cis, which is
coincident in a subgroup of alleles. Additional investigations will
be needed in order to further characterise the role of R462Q in
influencing prostate cancer risk.
CONCLUSION
Apart from the caucasian founder mutation E265X, a missense
change of unknown relevance, R400P, was observed in our study
samples. However, RNASEL does not account for a significant
number of familial prostate cancers in Germany, and the
penetrance of deleterious mutations may need further evaluation.
Common variants such as R462Q do not seem to influence prostate
cancer risk in our study population.
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type allele on the one hand, and patients with the altered genotype on the other hand.
cThe early-onset subsample comprises 49 probands (28 familial and 21 sporadic cases)
who were diagnosed at 55 years of age or younger.
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